Edgar Filing: ABIOMED INC - Form 4

ABIOMED INC Form 4 March 09, 2016 FORM 4 Check this box if no longer subject to Section 16. Form 5 obligations ary continue. See Instruction 16.									
(Print or Type	Kesponses)								
1. Name and Weber Day	Address of Reporting Pers /id M	Symbol	er Name an MED INC			0	5. Relationship of I Issuer		
(Last)	(First) (Midd		of Earliest T	-	-		(Check	all applicable)
C/O ABIO HILL DRI	MED, INC., 22 CHE VE		Day/Year) 2016			- 1	Director XOfficer (give to below) Chief O		Owner r (specify er
(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) X_Form filed by One Reporting Person								rson	
(City)	(State) (Zip	⁾⁾ Tal	ole I - Non-	Derivative	Secu		Person ired, Disposed of,	or Beneficial	v Owned
1.Title of Security (Instr. 3)	an	A. Deemed accution Date, if	3. Transactic Code		ties A sed of 4 and (A)	cquired (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
C			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock, \$.01 par value	03/07/2016		M <u>(5)</u>	8,111 (5)	A	\$ 5.86	125,761	D	
Common Stock, \$.01 par value	03/07/2016		S <u>(5)</u>	8,111 (5)	D	\$ 85.2095 <u>(6)</u>	117,650	D	
Common Stock, \$.01 par value	03/08/2016		M <u>(5)</u>	9,410 (5)	A	\$ 5.86	127,060	D	

Edgar Filing: ABIOMED INC - Form 4

Common					¢		
Stock,	02/08/2016	S ⁽⁵⁾	9,410	D	ወ 1000	117 (50)	D
\$.01 par	03/08/2016	3 <u>(3)</u>	(5)	D	85.1909	117,650	D
value					<u>(/)</u>		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	onDeriv Secur Acqu or Dia (D)	rities ired (A) sposed of : 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Share
Stock Option (right to buy) <u>(1)</u>	\$ 13.88						04/23/2008 <u>(2)</u>	04/23/2017	Common Stock	0
Stock Option (right to buy) <u>(1)</u>	\$ 13.8						05/23/2009 <u>(2)</u>	05/23/2018	Common Stock	0
Stock Option (right to buy) (3)	\$ 5.86	03/07/2016		M <u>(5)</u>		17,521 (5)	05/28/2010 <u>(2)</u>	05/28/2019	Common Stock	17,52
Stock Options (right to buy) (3)	\$ 5.86						03/31/2010(2)	05/28/2019	Common Stock	0
Stock Option (right to buy) (3)	\$ 10.03						06/03/2011 <u>(2)</u>	06/03/2020	Common Stock	0
Stock Option (right to	\$ 22.44						05/22/2013 <u>(2)</u>	05/22/2022	Common Stock	0

buy) (3)					
Stock Option (Right to Buy) (3)	\$ 23.15	05/14/2014(2)	05/14/2023	Common Stock	0
Stock Option (Right to Buy) (3)	\$ 21.55	05/14/2015 <u>(4)</u>	05/14/2024	Common Stock	0
Stock Option (right to buy) (<u>3)</u>	\$ 66.25	05/13/2016 <u>(4)</u>	05/13/2025	Common Stock	0

Reporting Owners

Reporting Owner Name / Address	Relationships					
I. S.	Director	10% Owner	Officer	Other		
Weber David M C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923			Chief Operating Officer			
Signatures						
/s/ Stephen C. McEvoy (by pow attorney)	ver of		03/09/2016			

Date

Explanation of Responses:

**Signature of Reporting Person

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- (2) This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (3) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (4) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (5) Sale of common stock pursuant to reporting owner's 10b5-1 plan.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$85.0000(6) and \$85.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$85.0000

(7) and \$85.8700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: ABIOMED INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.